TLR7 and neoplasm: SZU-106, a small-molecule TLR7 agonist, linked to the cell surface with a pegylated linker to produce a novel whole-tumor-cell vaccine, showed immune-activating responses in both in vitro and in vivo experiments, with a great potential to treat advanced malignant tumors [126].